CYTK
CYTOKINETICS INC
Next earnings Aug 5, 2026 · consensus $-1.70 EPS, $17.7M rev
Last earnings +16.7% on 2026-05-05
$86.49
▼ -0.88%$86.49▲ +160.83%
over 1Y
L $33.04H $87.26
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.9%
1W+7.0%
1M+22.0%
3M+29.6%
YTD+40.1%
1Y+160.8%
Avoid
Conviction
Horizon
Long (>12mo)
Street · 28 analysts
Buy
Cash-burning biotech with negative equity and a $9.7B valuation on $88M sales — a binary bet, not an investment.
Revenue (FY2025) $88.0M · FY2025
Cytokinetics is a cardiac-focused biopharma in the early stages of commercializing its muscle-biology franchise. Revenue inflected sharply in FY2025, up 376.6% to $88.0M as a product launch began, but that is dwarfed by the loss profile: net loss of -$785M (widened 33.2%), operating loss of -$612M, and diluted EPS of -$6.54. R&D spend rose 22.6% to $416M. The company has lost money every year shown (FY2021 -$215M through FY2025 -$785M), with an accumulated deficit of -$3.49B in retained earnings.
The balance sheet is the disqualifier. Stockholders' equity is negative at -$660M, total liabilities of $2.08B exceed total assets of $1.42B, and the liabilities/equity ratio is a meaningless -3.16x. Most acute: operating cash flow was -$510M against just $123M of cash on hand, so the company is wholly dependent on external financing — it has already added debt (long-term debt up 164.3% to $246M, current portion up 257.5%) and equity (shares up 4.0%) and will need more. This is a near-term funding-cliff situation absent a successful capital raise or a step-change in product revenue.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:48 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $70.4M | $94.6M | $7.53M | $18.5M | $88.0M |
| Gross profit | — | — | — | — | — |
| Operating income | -$186M | -$324M | -$496M | -$536M | -$612M |
| Net income | -$215M | -$389M | -$526M | -$590M | -$785M |
| Diluted EPS | -$2.80 | -$4.33 | -$5.45 | -$5.26 | -$6.54 |
| Net margin | -305.7% | -411.2% | -6988.6% | -3191.1% | -891.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$11.9B
EV / EBITDA—
EV / Sales135.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-6.7%
FCF yield-4.6%
Quality & risk
ROIC (est.)—
Free cash flow-$535M
Total debt$288M
Net cash-$165M
Altman Z-Score-0.80 distress
Piotroski F-Score2/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+4.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗4Period ending 2026-07-012026-07-02open ↗4Period ending 2026-07-012026-07-02open ↗4Period ending 2026-07-012026-07-02open ↗144Filing2026-07-01open ↗4Period ending 2026-06-242026-06-29open ↗4Period ending 2026-06-292026-06-29open ↗144Filing2026-06-29open ↗144Filing2026-06-26open ↗144Filing2026-06-24open ↗4Period ending 2026-06-232026-06-23open ↗4Period ending 2026-06-152026-06-15open ↗4Period ending 2026-06-092026-06-09open ↗
Frequently asked
- Is CYTOKINETICS INC (CYTK) a buy?
- CYTK currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Cash-burning biotech with negative equity and a $9.7B valuation on $88M sales — a binary bet, not an investment.
- What is CYTOKINETICS INC's quality score?
- CYTK scores 37.01799785765999/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001061983, latest 10-Q filed 2026-05-05) · EODHD · Proprietary analysis · as of 6/21/2026, 8:48:42 PM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.